Swiss National Bank Has $6.64 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Swiss National Bank grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,400 shares of the company's stock after buying an additional 3,300 shares during the period. Swiss National Bank owned approximately 0.15% of Krystal Biotech worth $6,642,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter worth $40,000. Avanza Fonder AB bought a new stake in shares of Krystal Biotech in the fourth quarter worth about $119,000. KBC Group NV raised its position in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the period. Blue Trust Inc. grew its position in shares of Krystal Biotech by 74.4% in the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares during the period. Finally, US Bancorp DE increased its stake in Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after purchasing an additional 82 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Remove Ads

Analysts Set New Price Targets

Several research firms have recently weighed in on KRYS. HC Wainwright reiterated a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Jefferies Financial Group began coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Chardan Capital increased their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Trading Down 2.7 %

Shares of NASDAQ:KRYS traded down $5.20 during trading on Wednesday, hitting $187.10. 185,924 shares of the company were exchanged, compared to its average volume of 283,717. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of 62.58 and a beta of 0.87. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The firm has a fifty day moving average price of $168.54 and a two-hundred day moving average price of $173.68.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company's quarterly revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 earnings per share. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).